Company / Operating Income
Anixa Biosciences Inc Operating Income History
FY2014-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$13.8M
FY2024
5-year range
-$14.3M / -$11.9M
FY2020-FY2024
Trend
+0.3%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Income returned to growth in FY2024 after 2 years of decline, reaching -$14M.
Based on SEC 10-K filings.
-$14M in FY2024.
Declined from -$13M to -$14M over the past 2 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2024, operating income increased 0.3% year-over-year.
- Peak operating income was recorded in FY2016.
- Lowest operating income in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.53 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$13.8M | +0.3% |
| FY2023 | -$13.9M | -5.6% |
| FY2022 | -$13.1M | -10.5% |
| FY2020 | -$11.9M | +16.8% |
| FY2019 | -$14.3M | -135.2% |
| FY2018 | -$6.1M | -34.7% |
| FY2017 | -$4.5M | -377.3% |
| FY2016 | -$944.8K | +81.3% |
| FY2015 | -$5.0M | +36.3% |
| FY2014 | -$7.9M | -57.5% |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026